in vivo News and Research

RSS

VisualSonics demonstrates Vevo LAZR imaging system at AACR conference

VisualSonics Inc., a leader in real time, in vivo, high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc., is demonstrating the recently announced Vevo LAZR Photoacoustics Imaging system at the American Association of Cancer Research's annual conference.

5 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers.

1 Apr 2011

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark Pharmaceuticals announces the discovery and initiation of IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR 401, an anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark's Biologics Research Centre located in Switzerland.

1 Apr 2011

NCI awards Case Western Reserve with $1.6 million grant for cancer research

Case Western Reserve University School of Medicine has received a $1.6 million grant from the National Cancer Institute to study how tumor cells avoid detection by the body's immune system, allowing cancer to develop and spread.

1 Apr 2011

First MR images to show complete borders in human cerebral cortex

Understanding functional properties of the brain’s structural units is one of the main aims of brain research. Until now only fragmentary borders of brain areas could be identified in vivo since the resolution in MR images was not high enough.

31 Mar 2011

Cellectis 2010 total operating revenues increase 55% to EUR 15.8M

Cellectis, the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.

31 Mar 2011

Pathfinder cell-based therapy reverses diabetes in mouse model

Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model.

30 Mar 2011

Eya1 phosphatase controls fate of embryonic lung epithelial stem cells

Investigators at The Saban Research Institute of Children's Hospital Los Angeles have provided the first evidence that Eya1 protein phosphatase is a crucial regulator of the development of embryonic lung epithelial stem cells.

30 Mar 2011

VisualSonics introduces Vevo LAZR system to advance cancer research

VisualSonics Inc., a leader in real-time, in vivo, high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc., today announced the launch of the Vevo LAZR Photoacoustics Imaging system for the advancement of cancer research in the pre-clinical imaging market.

25 Mar 2011

Columbia University, Sanofi-aventis collaborate to develop innovative diabetes medicines

Sanofi-aventis announced today a research collaboration with Columbia University Medical Center for the development of innovative diabetes medicines.

25 Mar 2011

Researchers create nanosurfaces to seal leg prosthetics against bacteria entry

In recent years, researchers have worked to develop more flexible, functional prosthetics for soldiers returning home from battlefields in Afghanistan or Iraq with missing arms or legs. But even new prosthetics have trouble keeping bacteria from entering the body through the space where the device has been implanted.

23 Mar 2011

Rxi's new RNAi preclinical data to be presented at Keystone conference

RXi Pharmaceuticals Corporation, a recognized leader in RNA interference based therapeutic discovery and development, today announced that new preclinical data using proprietary self-delivering RNAi compounds, including RXI-109, will be presented at the Keystone Symposia's Mechanism and Biology of Silencing conference being held March 20-25, 2011 in Monterey, California.

22 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment.

16 Mar 2011

Malaria drug shrinks, slows resistant pancreatic tumors

Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis.

16 Mar 2011

Anti-cancer drug loaded microcarriers successfully guided to targeted area in the liver

Soon, drug delivery that precisely targets cancerous cells without exposing the healthy surrounding tissue to the medication's toxic effects will no longer be an oncologist's dream but a medical reality, thanks to the work of Professor Sylvain Martel, Director of the Nanorobotics Laboratory at Polytechnique Montr-al.

16 Mar 2011